Chiu et al. (16) reported that ADAM9 could downregulate the expression of miRNA-1 through the activation of the EGFR signaling pathway, boosting the expression of CDCP1 and thereby promoting lung cancer progression. This evidence concerns the gene CDCP1 and lung carcinoma.